SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads

被引：6

作者：

Ghosh, Arun K. ^{[1
,2
]}

Shahabi, Dana ^{[1
,2
]}

Imhoff, Mackenzie E. C. ^{[3
]}

Kovela, Satish ^{[1
,2
]}

Sharma, Ashish ^{[1
,2
]}

Hattori, Shin-ichiro ^{[4
]}

Higashi-Kuwata, Nobuyo ^{[4
]}

Mitsuya, Hiroaki ^{[4
,5
,6
]}

Mesecar, Andrew D. ^{[7
]}

机构：

[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA

[2] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA

[3] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA

[4] Natl Ctr Global Hlth & Med, Dept Refractory Viral Dis, Shinjuku Ku, Tokyo 1628655, Japan

[5] Kumamoto Univ Hosp, Dept Clin Sci, Kumamoto 8608556, Japan

[6] Natl Canc Inst, HIV & AIDS Malignancy Branch, Expt Retrovirol Sect, Bethesda, MD 20817 USA

[7] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2023年 / 96卷

关键词：

Antiviral; Covid-19; Inhibitor; SARS-CoV-2; protease; Synthesis;

D O I：

10.1016/j.bmcl.2023.129489

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report here the synthesis and biological evaluation of a series of small molecule SARS-CoV-2 PLpro inhibitors. We compared the activity of selected compounds in both SARS-CoV-1 and SARS-CoV-2 PLpro inhibitory and antiviral assays. We have synthesized and evaluated several new structural variants of previous leads against SARS-CoV-2 PLpro. The replacement of the carboxamide functionality with sulfonamide derivatives resulted in PLpro inhibitors with potent PLpro inhibitory and antiviral activity in VeroE6 cells similar to GRL0617. To obtain molecular insight, we created an optimized model of a potent sulfonamide derivative in the SARS-CoV-2 PLpro active site.

引用

页数：6

共 50 条

[41] Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
Glaucio Monteiro Ferreira
Thanigaimalai Pillaiyar
Mario Hiroyuki Hirata
Antti Poso
Thales Kronenberger
Scientific Reports, 12
[42] Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease
Li, Kan
Jadhav, Prakash
Wen, Yu
Tan, Haozhou
Wang, Jun
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025,
[43] Inhibitor induced conformational changes in SARS-COV-2 papain-like protease
Ferreira, Glaucio Monteiro
Pillaiyar, Thanigaimalai
Hirata, Mario Hiroyuki
Poso, Antti
Kronenberger, Thales
SCIENTIFIC REPORTS, 2022, 12 (01)
[44] Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?
Maiti, Biplab K.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 1017 - 1019
[45] In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease
Huynh, Tien
Cornell, Wendy
Luan, Binquan
FRONTIERS IN CHEMISTRY, 2021, 8
[46] Characterization and Noncovalent Inhibition of the Deubiquitinase and delSGylase Activity of SARS-CoV-2 Papain-Like Protease
Freitas, Brendan T.
Durie, Ian A.
Murray, Jackelyn
Longo, Jaron E.
Miller, Holden C.
Crich, David
Hogan, Robert Jeff
Tripp, Ralph A.
Pegan, Scott D.
ACS INFECTIOUS DISEASES, 2020, 6 (08): : 2099 - 2109
[47] Identification of novel allosteric sites of SARS-CoV-2 papain-like protease (PLpro) for the development of COVID-19 antivirals
Ferreira, Juliana C.
Villanueva, Adrian J.
Al Adem, Kenana
Fadl, Samar
Alzyoud, Lara
Ghattas, Mohammad A.
Rabeh, Wael M.
JOURNAL OF BIOLOGICAL CHEMISTRY, 2024, 300 (11)
[48] A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro) Inhibitors
Chia, C. S. Brian
Lim, Siew Pheng
CHEMMEDCHEM, 2023, 18 (16)
[49] Development of a Fluorescence Polarization Assay for the SARS-CoV-2 Papain-like Protease
Li, Kan
Jadhav, Prakash
Wen, Yu
Tan, Haozhou
Wang, Jun
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025, 8 (03) : 774 - 784
[50] Preparation and characterization of nanobodies targeting SARS-CoV-2 papain-like protease
Qiao, Huarui
Li, Lingyun
Wang, Lu
Yu, Haijun
Hu, Fangzheng
Zhou, Xin
Yang, Hongzhao
Xu, Jianfeng
Meng, Xiangjing
Geng, Yong
Dai, Yuanyuan
PROTEIN EXPRESSION AND PURIFICATION, 2023, 207

← 1 2 3 4 5 →